Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Total Current Liabilities (2023 - 2026)

MBX Biosciences has reported Total Current Liabilities over the past 4 years, most recently at $14.6 million for Q1 2026.

  • Quarterly results put Total Current Liabilities at $14.6 million for Q1 2026, up 38.98% from a year ago — trailing twelve months through Mar 2026 was $14.6 million (up 38.98% YoY), and the annual figure for FY2025 was $15.5 million, up 40.21%.
  • Total Current Liabilities reached $14.6 million in Q1 2026 per MBX's latest filing, down from $15.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $15.5 million in Q4 2025 and bottomed at $3.9 million in Q4 2023.
  • Median Total Current Liabilities over the past 4 years was $11.4 million (2024), compared with a mean of $11.3 million.
  • The largest annual shift saw Total Current Liabilities surged 181.48% in 2024 before it rose 10.46% in 2025.
  • Over 4 years, Total Current Liabilities stood at $3.9 million in 2023, then soared by 181.48% to $11.1 million in 2024, then skyrocketed by 40.21% to $15.5 million in 2025, then fell by 5.99% to $14.6 million in 2026.
  • Business Quant data shows Total Current Liabilities for MBX at $14.6 million in Q1 2026, $15.5 million in Q4 2025, and $12.1 million in Q3 2025.